Highlight
– PET-guided BrECADD chemotherapy achieves an 82% complete remission rate in older patients with advanced-stage classic Hodgkin lymphoma (AS-cHL).
– Treatment is feasible with 89% of patients completing the prescribed cycles and no treatment-related deaths.
– Two-year progression-free survival (PFS) and overall survival (OS) rates exceed 90%, matching outcomes seen in younger populations.
– Health-related quality of life (HRQoL), initially impaired, improves post-treatment to approach general population norms.
